From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
Clinical data
Trade namesAimovig
ATC code
Legal status
Legal status
  • US: ℞-only
CAS Number
  • none
Chemical and physical data
Molar mass145.9 kDa g·mol−1

Erenumab (trade name Aimovig) is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.[1][2][3] It was the first of the group of CGRPR antagonists to be approved in 2018.[4]


Erenumab is approved for prevention of migraine in adults.[5]

It is administered by subcutaneous injection of 70 or 140 mg once a month.[6]


Erenumab is a fully humanized monoclonal antibody of the calcitonin gene-related peptide receptor (CGRPR).[6]



This medication was developed by Amgen Inc.[3]

In the phase III STRIVE clinical trial 955 patients were divided into three groups in a 1:1:1 ratio. Each group was injected subcutaneously monthly with 0, 70 or 140 mg erenumab over a period of 6 months. The results were measured as mean monthly migraine days in months 4, 5, and 6. At baseline the patients experienced between 4 and 14 migraine days per month with an average of 8.3. The medication significantly reduced the number of migraine days per month by 3.2 in the 70-mg group and 3.7 in the 140-mg group, versus 1.8 in the placebo (0-mg) group.[3][7]

Approval and marketing[edit]

The United States Food and Drug Administration approved the medication for the preventive treatment of migraine in adults on May 17, 2018. The list price was reported to be US$6,900 per year.[8] It was licensed by the European Medicines Agency on July 31, 2018[9] and is being evaluated by the National Institute for Health and Care Excellence as of September 2018.[10]

See also[edit]


  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Erenumab" (PDF). American Medical Association. November 24, 2015. Archived (PDF) from the original on 2018-11-04. Retrieved 4 November 2018.
  2. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  3. ^ a b c Goadsby; et al. (2017). "A Controlled Trial of Erenumab for Episodic Migraine". N. Engl. J. Med. (377:2123–2132).
  4. ^ "FDA Approves First-in-Class Drug Erenumab (Aimovig) for Migraine Prevention".
  5. ^ "Medscape Log In".
  6. ^ a b "Aimovig (erenumab-aooe) FDA Approval History -".
  7. ^ Erenumab to prevent migraine: results from phase III STRIBE", Pharma World, December 14, 2017.
  8. ^ Gina Kolata (May 17, 2018), "New Drug Offers Hope to Millions With Severe Migraines", The New York Times.
  9. ^ "First drug to prevent chronic migraines approved by EU". The Guardian. 31 July 2018. Retrieved 19 September 2018.
  10. ^ "Erenumab for preventing migraine [ID1188] | Guidance and guidelines | NICE". National Institute for Health and Care Excellence. Retrieved 19 September 2018.